Revlimid vs Imbruvica
Side-by-side drug price comparison from Medicare Part D data
Verdict
Imbruvica costs 18% less per claim than Revlimid ($10445.00 vs $12786.00). Imbruvica has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Imbruvica at $5.7B.
| Metric | Revlimid | Imbruvica |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786 | $10,445* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $5.7B |
| Total Claims | 612,000 | 548,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4% | -8.7%* |
| Generic Available | No | Yes |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 58,000 | 48,000 |
Imbruvica costs 18% less per claim than Revlimid ($10445.00 vs $12786.00). Imbruvica has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Imbruvica at $5.7B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Revlimid and Imbruvica. What follows is the interpretation — which specific axes carry the most weight for Revlimid versus Imbruvica, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual Revlimid and Imbruvica detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.